These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [How to enhance the efficacy of radiotherapy]. Calais G Rev Prat; 1994 Apr; 44(8):1021-5. PubMed ID: 7939318 [TBL] [Abstract][Full Text] [Related]
25. A heterogeneous dose distribution in simultaneous integrated boost: the role of the clonogenic cell density on the tumor control probability. Strigari L; D'Andrea M; Abate A; Benassi M Phys Med Biol; 2008 Oct; 53(19):5257-73. PubMed ID: 18758004 [TBL] [Abstract][Full Text] [Related]
26. Impact of tumor repopulation on radiotherapy planning. Wang JZ; Li XA Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615 [TBL] [Abstract][Full Text] [Related]
27. The potential for improving radiotherapy outcome by improving the oxygen supply to solid tumours. Denekamp J; Waites A Strahlenther Onkol; 1996 Nov; 172 Suppl 2():22-3. PubMed ID: 8946041 [No Abstract] [Full Text] [Related]
28. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer. Xiong W; Li J; Ma CM Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338 [TBL] [Abstract][Full Text] [Related]
29. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Moeller BJ; Richardson RA; Dewhirst MW Cancer Metastasis Rev; 2007 Jun; 26(2):241-8. PubMed ID: 17440683 [TBL] [Abstract][Full Text] [Related]
30. Dose prescription and optimisation based on tumour hypoxia. Toma-Daşu I; Daşu A; Brahme A Acta Oncol; 2009; 48(8):1181-92. PubMed ID: 19863227 [TBL] [Abstract][Full Text] [Related]
31. [Probabilities of organs at risk damage: history and mathematical models]. Rezvoy N; Dubray B Cancer Radiother; 2010 Jul; 14(4-5):241-5. PubMed ID: 20598614 [TBL] [Abstract][Full Text] [Related]
32. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Søvik A; Malinen E; Skogmo HK; Bentzen SM; Bruland OS; Olsen DR Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1496-504. PubMed ID: 17674980 [TBL] [Abstract][Full Text] [Related]
34. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Gay HA; Niemierko A Phys Med; 2007 Dec; 23(3-4):115-25. PubMed ID: 17825595 [TBL] [Abstract][Full Text] [Related]
35. The impact of tissue microenvironment on treatment simulation. Daşu A; Denekamp J Adv Exp Med Biol; 2003; 510():63-7. PubMed ID: 12580406 [No Abstract] [Full Text] [Related]
36. The clinical and biologic basis for radiation therapy of cutaneous carcinoma, melanoma, and lymphoma. Massullo V Adv Dermatol; 1995; 10():201-42; discussion 243. PubMed ID: 7794672 [No Abstract] [Full Text] [Related]
37. Should the delta-TCP concept be replaced by "local control probability ratios"? Vaarkamp J; Zhu Y Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):614-7. PubMed ID: 11012311 [No Abstract] [Full Text] [Related]
38. Development of an integrated Monte Carlo model for glioblastoma multiforme treated with boron neutron capture therapy. Moghaddasi L; Bezak E Sci Rep; 2017 Aug; 7(1):7069. PubMed ID: 28765533 [TBL] [Abstract][Full Text] [Related]
39. TCP modelling - why is it important? Carlone M; Nahum A; Stavrev P Acta Oncol; 2010 Nov; 49(8):1205. PubMed ID: 20950225 [No Abstract] [Full Text] [Related]
40. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution. Keall PJ; Webb S Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]